SCHEMBL4196459

SCHEMBL4196459

CS(=O)(=O)Nc1cccc(-c2cncc(NCc3ccoc3)c2)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FYN P06241 1/20 0.67
BRAF P15056 1/20 0.50
CYP1A2 P05177 12/20 0.48
CYP3A4 P08684 12/20 0.48
CYP2D6 P10635 11/20 0.48
CYP2C19 P33261 11/20 0.48
HSD17B10 Q99714 8/20 0.48
CYP2C9 P11712 7/20 0.48
USP2 O75604 5/20 0.48
ALOX15 P16050 2/20 0.48
PIP4K2A P48426 2/20 0.47
PIP4K2B P78356 2/20 0.47
PIK3CA P42336 2/20 0.47
EGFR P00533 1/20 0.47
ALDH1A1 P00352 7/20 0.46
HPGD P15428 6/20 0.46
TSHR P16473 5/20 0.46
KDM4E B2RXH2 4/20 0.46
TDP1 Q9NUW8 2/20 0.46
MAPT P10636 4/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4191781 0.83 BRAF (0.71) FYNBRAFPIP4K2APIP4K2BHPGD
SCHEMBL4191577 0.82 CYP1A2 (0.53) FYNCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL4191563 0.81 FYN (0.56) FYNBRAFCYP1A2CYP3A4CYP2D6
SCHEMBL30521649 0.81 FYN (1.00) FYNBRAFCYP3A4CYP2C9PIK3CA
SCHEMBL4196870 0.81 FYN (1.00) FYNBRAFCYP3A4CYP2C9PIK3CA
SCHEMBL4187248 0.80 CYP1A2 (0.48) FYNCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL4189042 0.80 CYP1A2 (0.48) CYP1A2CYP3A4CYP2D6CYP2C19HSD17B10
SCHEMBL4192414 0.80 FYN (0.77) FYNBRAFCYP1A2CYP3A4CYP2D6
SCHEMBL4192356 0.79 BRAF (0.53) BRAFCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL4194118 0.79 FYN (0.72) FYNBRAFCYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090196912-A1 Pyridinylamines GPC BOTECH AG (DE) 2009-08-06 US claimed
EP-1789393-A2 PYRIDINYLAMINES GPC Biotech AG (DE) 2007-05-30 EP claimed
WO-2006010637-A2 PYRIDINYLAMINES GPC BIOTECH AG (DE) 2006-02-02 WO claimed
US-20200206188-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO BROWN DENNIS M (US) 2020-07-02 US disclosed
US-10383847-B2 Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo BROWN DENNIS M (US) 2019-08-20 US disclosed
US-20160243077-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO BROWN DENNIS M (US) 2016-08-25 US disclosed
US-20090196912-A1 Pyridinylamines GPC BOTECH AG (DE) 2009-08-06 US disclosed
EP-1789393-A2 PYRIDINYLAMINES GPC Biotech AG (DE) 2007-05-30 EP disclosed
WO-2006010637-A2 PYRIDINYLAMINES GPC BIOTECH AG (DE) 2006-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10383847-B2 Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo NEK9, NEK7, NEK3 FYN 3292/4885BRAF 3225/4885CYP1A2 349/4885
US-20200206188-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO NEK9, NEK7, NEK3 FYN 3292/4885BRAF 3225/4885CYP1A2 349/4885
US-20160243077-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO NEK9, NEK7, NEK3 FYN 3292/4885BRAF 3225/4885CYP1A2 349/4885
US-20090196912-A1 Pyridinylamines PRNP, PLPBP, SNCA FYN 173/4885BRAF 1471/4885CYP1A2 775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.